ES2562022T3 - Estimulación del sistema inmunitario con polidextrosa - Google Patents

Estimulación del sistema inmunitario con polidextrosa Download PDF

Info

Publication number
ES2562022T3
ES2562022T3 ES02799071.2T ES02799071T ES2562022T3 ES 2562022 T3 ES2562022 T3 ES 2562022T3 ES 02799071 T ES02799071 T ES 02799071T ES 2562022 T3 ES2562022 T3 ES 2562022T3
Authority
ES
Spain
Prior art keywords
polydextrose
immune system
stimulation
mammal
iga
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES02799071.2T
Other languages
English (en)
Inventor
Nina Rautonen
Juha Apajalahti
Kirsti Tiihonen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
International N&H Denmark ApS
Original Assignee
DuPont Nutrition Biosciences ApS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DuPont Nutrition Biosciences ApS filed Critical DuPont Nutrition Biosciences ApS
Application granted granted Critical
Publication of ES2562022T3 publication Critical patent/ES2562022T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A23L33/25—Synthetic polymers, e.g. vinylic or acrylic polymers
    • A23L33/26—Polyol polyesters, e.g. sucrose polyesters; Synthetic sugar polymers, e.g. polydextrose
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/195—Antibiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Polymers & Plastics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Animal Husbandry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)
  • Feed For Specific Animals (AREA)
  • Fodder In General (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

El uso de polidextrosa en la preparación de una composición para estimular el sistema inmunitario del tracto gastrointestinal de un mamífero, que comprende mezclar al menos un excipiente o vehículo farmacológicamente aceptable con polidextrosa, siendo dicha polidextrosa eficaz para el aumento de la concentración de inmunoglobulina A (IgA) en el intestino de dicho mamífero.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14

Claims (1)

  1. imagen1
    imagen2
ES02799071.2T 2002-01-15 2002-12-23 Estimulación del sistema inmunitario con polidextrosa Expired - Lifetime ES2562022T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FI20020078A FI20020078A7 (fi) 2002-01-15 2002-01-15 Immuunijärjestelmän stimulointi polydextroosilla
FI20020078 2002-01-15
PCT/EP2002/014719 WO2003059333A2 (en) 2002-01-15 2002-12-23 Stimulation of the immune system with polydextrose

Publications (1)

Publication Number Publication Date
ES2562022T3 true ES2562022T3 (es) 2016-03-02

Family

ID=8562798

Family Applications (1)

Application Number Title Priority Date Filing Date
ES02799071.2T Expired - Lifetime ES2562022T3 (es) 2002-01-15 2002-12-23 Estimulación del sistema inmunitario con polidextrosa

Country Status (10)

Country Link
US (1) US20030157146A1 (es)
EP (1) EP1465505B1 (es)
JP (1) JP4793533B2 (es)
KR (1) KR101007512B1 (es)
AU (1) AU2002364298B2 (es)
CA (1) CA2473209C (es)
ES (1) ES2562022T3 (es)
FI (1) FI20020078A7 (es)
NZ (1) NZ534246A (es)
WO (1) WO2003059333A2 (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1377280T3 (da) * 2001-04-09 2007-10-08 Danisco Usa Inc Fyldmidler som mæthedsfornemmelsesgivende midler
JP2004049093A (ja) * 2002-07-18 2004-02-19 Meiji Milk Prod Co Ltd 腸内酪酸上昇食品組成物および医薬品
FI119429B (fi) * 2002-09-17 2008-11-14 Danisco Hiilihydraattien uusi käyttö ja koostumukset
EP1629730A1 (en) * 2004-08-12 2006-03-01 First-to-Market N.V. Functional sugar replacement
KR100983450B1 (ko) * 2005-04-28 2010-09-20 히다치 가세고교 가부시끼가이샤 식품보충제에 대한 개별적 다양성 평가의 모델로서 전혈내의 생체 외 유전자 발현
US7572474B2 (en) * 2005-06-01 2009-08-11 Mead Johnson Nutrition Company Method for simulating the functional attributes of human milk oligosaccharides in formula-fed infants
JP4800384B2 (ja) 2005-06-08 2011-10-26 ヒタチ ケミカル リサーチ センター インコーポレイテッド 腫瘍細胞及び刺激された白血球におけるｍＲＮＡの発現プロファイルに基づく腫瘍性疾患に対する免疫応答を予測する方法
US8075934B2 (en) * 2008-10-24 2011-12-13 Mead Johnson Nutrition Company Nutritional composition with improved digestibility
US8287931B2 (en) * 2005-06-30 2012-10-16 Mead Johnson Nutrition Company Nutritional composition to promote healthy development and growth
US20070048358A1 (en) * 2005-08-31 2007-03-01 Schorr Phillip A Antimicrobial substrates
US20070048344A1 (en) * 2005-08-31 2007-03-01 Ali Yahiaoui Antimicrobial composition
US20070048356A1 (en) * 2005-08-31 2007-03-01 Schorr Phillip A Antimicrobial treatment of nonwoven materials for infection control
ATE518011T1 (de) 2006-04-07 2011-08-15 Hitachi Chemical Co Ltd Erhöhte expression von t- zellenrezeptorvermittelter tumornekrosefaktorsuperfamilie und chemokin-mrna in peripheren blut leukozyten bei patienten mit morbus& xa;crohn
GB2448106B (en) * 2007-02-23 2011-10-26 Cadbury Schweppes Plc Candy compositon with fibre-containing centrefill
EP2209919A4 (en) 2007-11-14 2011-04-13 Hitachi Chemical Co Ltd ENHANCED EXPRESSION OF FC RECEPTOR TUMOR NECROSIS NECROSIS FACTOR SUPERFAMILY IN THE PERIFERIC BLOOD LEUKOCYTES
US8986769B2 (en) * 2008-10-24 2015-03-24 Mead Johnson Nutrition Company Methods for preserving endogenous TGF-β
US20110229471A1 (en) 2008-11-26 2011-09-22 Cedars-Sinai Medical Center Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease
US9580752B2 (en) 2008-12-24 2017-02-28 Cedars-Sinai Medical Center Methods of predicting medically refractive ulcerative colitis (MR-UC) requiring colectomy
US8425955B2 (en) 2009-02-12 2013-04-23 Mead Johnson Nutrition Company Nutritional composition with prebiotic component
US8293264B2 (en) * 2009-05-11 2012-10-23 Mead Johnson Nutrition Company Nutritional composition to promote healthy development and growth
FR2974512B1 (fr) * 2011-04-28 2013-11-08 Roquette Freres Composition anti-inflammatoire de l'intestin comprenant du maltitol
BR112014010660A2 (pt) * 2011-11-04 2017-05-09 Gen Mills Inc métodos e composições para modular bactéria gastrointestinal
KR102343212B1 (ko) 2013-03-27 2021-12-23 세다르스-신나이 메디칼 센터 Tl1a 기능 및 관련된 신호전달 경로의 저해에 의한 섬유증 및 염증의 완화 및 반전
WO2015010108A1 (en) 2013-07-19 2015-01-22 Cedars-Sinai Medical Center Signature of tl1a (tnfsf15) signaling pathway
ITMI20131467A1 (it) * 2013-09-06 2015-03-07 Sofar Spa Uso di una composizione comprendente microrganismi per aumentare la produzione intestinale di acido butirrico, di acido folico o di niacina e/o per diminuire la produzione intestinale di acido succinico
MA39710A (fr) 2014-04-23 2015-10-29 Sofar Spa Composition topique destinée à être utilisée dans le traitement d'une maladie inflammatoire de l'intestin
DE112016003948T5 (de) 2015-08-31 2018-05-09 City Of Sapporo Molekulare verfahren zum beurteilen einer urothelialen erkrankung
US11186872B2 (en) 2016-03-17 2021-11-30 Cedars-Sinai Medical Center Methods of diagnosing inflammatory bowel disease through RNASET2
IT201600083376A1 (it) 2016-08-08 2018-02-08 Sofar Spa Uso di probiotici per aumentare l’assorbimento proteico
ITUA20164188A1 (it) 2016-06-08 2017-12-08 Sofar Spa Nuovo uso medico di probiotici
IT201600122724A1 (it) 2016-12-02 2018-06-02 Sofar Spa Exopolysaccharides and uses thereof
IT201600127498A1 (it) 2016-12-16 2018-06-16 Sofar Spa Probiotici per uso nella diverticolosi e malattia diverticolare
JP7351472B2 (ja) * 2018-10-12 2023-09-27 日本食品化工株式会社 ＩｇＡ分泌促進用組成物
US11751597B2 (en) 2019-11-05 2023-09-12 Alfasigma S.P.A. Compositions comprising bacterial strains for use in increasing the bioavailability of amino acids derived from proteins, and related food product methods and systems
US20210195929A1 (en) * 2019-12-31 2021-07-01 Kraft Foods Group Brands Llc No sugar added multilayer edible products comprising a center and a barrier layer

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2436967A (en) * 1942-04-01 1948-03-02 Corn Prod Refining Co Polymerization of sugars
US2719179A (en) * 1951-01-25 1955-09-27 Mora Peter Tibor Branched-chain carbohydrate polymers and their preparation
US3766165A (en) * 1966-08-17 1973-10-16 Pfizer Polysaccharides and their preparation
FI73121C (fi) * 1985-08-08 1987-09-10 Valio Meijerien Vaextbefraemjande foder och tillsatsaemne foer anvaendning daeri.
US4659338A (en) * 1985-08-16 1987-04-21 The Lubrizol Corporation Fuel compositions for lessening valve seat recession
JPS62220169A (ja) * 1986-03-18 1987-09-28 Yakult Honsha Co Ltd 流動性食品
US5013722A (en) * 1986-06-06 1991-05-07 Hoffmann-Laroche Inc. Cholecystokinin analogs for controlling appetite
US4789664A (en) * 1986-12-19 1988-12-06 The Procter & Gamble Company Food compositions with superior blood cholesterol lowering properties
US4808701A (en) * 1987-03-30 1989-02-28 Hoffmann-La Roche Inc. Cyclic peptides having appetite regulating activity
US4965354A (en) * 1988-02-26 1990-10-23 Taito Company, Ltd. Process for producing a condensed polysaccharide
JP2802077B2 (ja) * 1988-09-07 1998-09-21 昭和産業株式会社 飲食品
US5098730A (en) * 1988-11-14 1992-03-24 Cultor Ltd. Dietetic sweetening composition
US5667593A (en) * 1989-01-26 1997-09-16 Cultor Ltd. Modified polydextrose and process therefor
US5051500A (en) * 1989-08-11 1991-09-24 A. E. Staley Manufacturing Company Method of preparing a randomly-bonded polysaccharide
US5378491A (en) * 1990-02-20 1995-01-03 A. E. Staley Manufacturing Co. Method of preparing a starch hydrolysate, an aqueous starch hydrolysate dispersion, method of preparing a food containing a starch hydrolysate, and a food formulation containing a starch hydrolysate
SE466130B (sv) * 1990-11-22 1992-01-07 Kabi Pharmacia Ab Gelbildande flytande dietfiberkomposition
EP0572424B1 (en) * 1991-02-20 1996-11-20 Pfizer Inc. Reduced polydextrose
US5336486A (en) * 1991-03-28 1994-08-09 Theratech, Inc. Appetite control method
FR2688800B1 (fr) * 1992-03-19 1995-06-16 Roquette Freres Procede de preparation de polysaccharides peu digestibles, eventuellement hydrogenes.
JP2654529B2 (ja) * 1992-03-27 1997-09-17 大塚製薬株式会社 健康飲料組成物
US5273754A (en) * 1992-03-27 1993-12-28 Mann Morris A Appetite suppressant composition and method relating thereto
DE69312851T2 (de) * 1992-04-10 1998-01-08 Otsuka Pharmaceutical Co., Ltd., Tokio/Tokyo Nahrungsmittelzusammensetzung zur hemmung von der bildung von darmverrottungsprodukten
US5322697A (en) * 1992-05-28 1994-06-21 Meyer James H Composition and method for inducing satiety
FR2697023B1 (fr) * 1992-10-16 1994-12-30 Roquette Freres Polymère soluble hypocalorique du glucose et procédé de préparation de ce polymère .
US5439893A (en) * 1993-05-26 1995-08-08 University Of Montana Methods for the treatment and prevention of diarrhea
US5728225A (en) * 1993-07-26 1998-03-17 Roquette Freres Viscous liquid compositions of xylitol and a process for preparing them
JP3310738B2 (ja) * 1993-11-10 2002-08-05 株式会社ロッテ 低カロリーチョコレート
FR2712891B1 (fr) * 1993-11-22 1996-02-02 Roquette Freres Procédé de purification d'un polymère soluble hypocalorique du glucose et produit ainsi obtenu.
US5843921A (en) * 1994-03-15 1998-12-01 Childrens Hospital Of Los Angeles Therapeutic food composition and method to diminish blood sugar fluctuations
FR2726829B1 (fr) * 1994-11-10 1997-01-17 Roquette Freres Composition de polyols, son procede de preparation et ses applications
US5527554A (en) * 1995-06-02 1996-06-18 Xyrofin Oy Bulk sweetener for frozen desserts
US5827526A (en) * 1995-07-11 1998-10-27 Abbott Laboratories Use of indigestible oligosaccharides to prevent gastrointestinal infections and reduce duration of diarrhea in humans
JP3426440B2 (ja) * 1996-01-18 2003-07-14 株式会社ロッテ 新規な脱乳糖乳・脱乳糖粉乳およびこれを含有する飲食物ならびに脱乳糖乳および脱乳糖粉乳の製造方法
ATE227521T1 (de) * 1996-07-31 2002-11-15 Sraffinerie Tirlemontoises Sa Fruktan- und/oder polydextrose enthaltende milchproduktpulver; verfahren zu ihrer herstellung und verwendung derselben
JP2000143519A (ja) * 1998-11-04 2000-05-23 Kao Corp 腸内低級脂肪酸生成促進剤
JP2001064181A (ja) * 1999-08-27 2001-03-13 Otsuka Pharmaceut Co Ltd 免疫賦活組成物
US6677318B1 (en) * 2000-09-05 2004-01-13 Beisel Guenther Cross-linked agent for generation of a long-lasting satiety effect and method for the production of the said
DK1377280T3 (da) * 2001-04-09 2007-10-08 Danisco Usa Inc Fyldmidler som mæthedsfornemmelsesgivende midler
FI119429B (fi) * 2002-09-17 2008-11-14 Danisco Hiilihydraattien uusi käyttö ja koostumukset

Also Published As

Publication number Publication date
EP1465505B1 (en) 2015-11-18
CA2473209A1 (en) 2003-07-24
WO2003059333A3 (en) 2003-12-11
JP4793533B2 (ja) 2011-10-12
NZ534246A (en) 2008-09-26
AU2002364298A1 (en) 2003-07-30
KR101007512B1 (ko) 2011-01-14
EP1465505A2 (en) 2004-10-13
US20030157146A1 (en) 2003-08-21
KR20040103914A (ko) 2004-12-09
AU2002364298B2 (en) 2009-01-15
WO2003059333A2 (en) 2003-07-24
JP2005523250A (ja) 2005-08-04
FI20020078A7 (fi) 2003-07-16
CA2473209C (en) 2011-09-20
FI20020078A0 (fi) 2002-01-15

Similar Documents

Publication Publication Date Title
ES2562022T3 (es) Estimulación del sistema inmunitario con polidextrosa
ES2528384T3 (es) Métodos de utilización de inhibidores del receptor de adenosina para potenciar la respuesta inmunitaria y la inflamación
ES2485316T3 (es) Usos inmunológicos de compuestos inmunomoduladores para vacunas y terapia anti-enfermedades infecciosas
ES2523837T3 (es) Agentes de unión específica al factor de crecimiento de hepatocitos
ES2522567T3 (es) Composición farmacéutica que comprende amlodipino y losartán
ES2526521T3 (es) Composiciones de antibiótico para el tratamiento del oído
CL2013003554A1 (es) Forma de dosificación farmacéutica sólida en forma de dispersión o solución sólida que comprende ritonavir, entre 50-80% en peso de al menos un polímero soluble en agua con una tg de al menos 50 °c, respecto del peso total de la forma de dosificación, y un tensoactivo (divisional de la sol.1844-2009 y esta divisional de la sol. 393-2006).
BRPI0314038B8 (pt) anticorpo humano isolado, molécula de ácido nucleico isolada, vetor, uso de um anticorpo, e, composição farmacêutica
DE60131703D1 (de) Orale feste pharmazeutische Zusammensetzungen zur pH-abhängig mehrphasigen Freisetzung
DE60316323D1 (de) Feste pharmazeutische formulierungen mit telmisartan
BRPI0412890A (pt) método de tratar uma doença em um indivìduo humano em necessidade do mesmo, composição farmacêutica, e, métodos de selecionar um composto para administração conjuntamente com um anticorpo terapêutico, e de aumentar a eficiência de um tratamento envolvendo a administração de um anticorpo terapêutico que pode ser ligado por cd16 em um indivìduo
UY29759A1 (es) Formulaciones de ibandronato mejoradas
DK0502814T3 (da) Præparater til at øge billedkontrasten i diagnostiske undersøgelser af mave-tarmkanalen hos patienter
CL2010000188A1 (es) Metodo para el tratamiento de una infeccion en un sujeto que comprende la administracion de 9-[(2,2-dimetil-propilamino)-metil]-minociclina o de una sal de la misma; composicion farmaceutica que comprende dicho compuesto; y su uso.
DE60304993D1 (de) In der mundhöhle dispergierbare pharmazeutische zusammensetzung mit agomelatin
CL2020003292A1 (es) Péptido que consiste en la secuencia de aminoácidos de seq id no: 2; anticuerpo que reconoce dicho péptido; receptor de linfocito t; célula hospedadora; linfocito t activado; composición farmacéutica; uso; y kit (divisional de la solicitud no. 201802969)
ES2505643T3 (es) Galectina para uso en el tratamiento del síndrome del ojo seco
ES2528420T3 (es) Utilización de un concentrado de inmunoglobulinas G (IgG) empobrecido en anticuerpos anti-A y anti-B para el tratamiento de ictericia neonatal por incompatibilidad feto-maternal en sistemas ABO
DE60205905D1 (de) Pharmazeutische zusammensetzung zur orale verabreichung mit verbesserter bioverfügbarkeit
ES2528307T3 (es) Método y sistema para eliminar el inhibidor de citoquina en pacientes
ATE457318T1 (de) Gegen das menschliche bst2 antigen gerichteter monoklonaler antikörper
BR0307320A (pt) Sistema de liberação osmótico
AR056137A1 (es) Un conjugado peptido inmunoglobulina y su uso como antiviral
BRPI0208124B8 (pt) uso de um anticorpo igy imunologicamente específico para a proteína paa associada à virulência de escherichia coli de ligação e eliminação (aeec)
DE69530380D1 (de) Retropeptide, antikörper dagegen und deren verwendungen in der impfung und in vitro diagnostik